Genialis’ Post

Novartis to Buy Radiology Drug Specialist Mariana for $1 Billion Upfront Novartis has agreed to acquire U.S. radiopharmaceutical company Mariana Oncology for $1 billion upfront, boosting its portfolio of precision cancer treatments in development, the Swiss drug manufacturer said this week. The deal includes up to $750 million of further payments upon achieving certain milestones, it added. Mariana Oncology is working on novel radioligand cancer therapies (RLTs) that have not yet been tested on humans. Radioligand therapy, based on cell-killing radioactive particles that are attached to tumor-seeking molecules, is one of three technologies that Novartis' development efforts are focused on, apart from cell and gene therapy as well as RNA. https://lnkd.in/gGBPrPrT #aspenalert #biotech #bioprocess

📢 Top cell therapy headlines from the last couple of weeks: 📢 ❇ AstraZeneca acquire Gracell Biotechnologies for around $1.2bn, including their FasTCAR rapid manufacturing platform and pipeline across oncology and autoimmunity   ❇ AbbVie and Umoja Biopharma entered a strategic collaboration with funding up to $1.44bn to develop in-situ CAR-Ts using their VivoVec™ gene delivery platform   ❇ Umoja Biopharma also secured a development partnership with IASO BioTherapeutics（驯鹿生物） to develop both ex vivo and in vivo CAR-Ts in oncology and autoimmunity   ❇ Boehringer Ingelheim and 3T Biosciences enter another strategic collaboration, with milestones up to $538.5m to further progress in their next-gen TCR-T programs   ❇ Boehringer Ingelheim have also licensed Enara Bio’s Dark Antigen® platform to develop off-the-shelf cancer immunotherapies ❇ Cabaletta Bio received fast track designations in Dermatomyositis and Systemic Sclerosis ❇ Kyverna Therapeutics move into MS Phase 2 trial ❇ Adicet Bio, Inc Bio receive IND approval for Lupus trial Hear from AstraZeneca, Cabaletta, Kyverna, Umoja and many more at the 7th CAR-TCR Summit Europe in just 5 weeks! See the full agenda now: https://ter.li/1a72bz

Gene&Cell Therapy >> Bladder cancer drugmaker CG Oncology files for IPO as biotech market shows signs of a rebound: CG Oncology, a late-stage California biotech developing a bladder cancer therapy, revealed its plans to go public on the Nasdaq in an SEC filing Tuesday night. The move marks the first IPO filing of 2024 for the biotech industry, which had a dismal 2023 until the last month, when signs of life began to emerge following a series of acquisitions and signals from the Fed that there would be interest rate cuts in 2024, meaning more capital will likely flow into drug development. While CG’s filing is the first of the new year, $CGON might not be the inaugural listing of 2024. Obesity gene therapy developer Fractyl Health had revealed its IPO plans in mid-December, meaning it could land on Wall Street ahead of CG and any other biotechs that might pencil in their plans before or during the rush of the JP Morgan Healthcare Conference next week. By the end of its first year on the public markets, CG could have topline data from a Phase III trial of its bladder cancer treatment candidate cretostimogene, per its S-1 filing. The biotech’s lead study, BOND-003, is testing the drug as a monotherapy in patients with BCG-unresponsive high-risk non-muscle invasive bladder cancer, or NMIBC. Formerly known as CG0070, the oncolytic virus is also being tested in combination with Merck’s Keytruda and in other NMIBC settings alone and in combination regimens. If the first Phase III trial is a success, CG plans to file for approval with a biologics license application. That could happen as soon as late 2024 or early 2025, CEO Arthur Kuan told Endpoints News at the time of the biotech’s $105 million crossover round in August 2023. Less than three months later, the biotech had confidentially filed its IPO plans with the SEC, according to documents revealed Tuesday. What started as Cold Genesys in 2010 is now one of multiple companies creating therapies for bladder cancer, including UroGen, which also plans a 2024 approval request; ImmunityBio, which just secured more money this week as it awaits an April PDUFA following a May 2023 rejection; and gene therapy biotech enGene, which began trading on the Nasdaq after a SPAC combination last November. CG is first attempting to treat patients who are unresponsive to Merck’s Bacillus Calmette-Guérin therapy, which has been in short supply for the past few years. “More than 20,000 patients may not have access to BCG, and that accumulates because that shortage is not going away,” Kuan said in the August interview. The company has ramped up spending over the past two years as it goes through late-stage development, but it still has a hefty balance sheet with $203.7 million in cash, equivalents and marketable securities at the end of September. In the first nine months of 2023, it spent $29.8… #lucidquest #genetherapy #celltherapy

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> Bladder cancer drugmaker CG Oncology files for IPO as biotech market shows signs of a rebound: CG Oncology, a late-stage California biotech developing a bladder cancer therapy, revealed its plans to go public on the Nasdaq in an SEC filing Tuesday night. The move marks the first IPO filing of 2024 for the biotech industry, which had a dismal 2023 until the last month, when signs of life began to emerge following a series of acquisitions and signals from the Fed that there would be interest rate cuts in 2024, meaning more capital will likely flow into drug development. While CG’s filing is the first of the new year, $CGON might not be the inaugural listing of 2024. Obesity gene therapy developer Fractyl Health had revealed its IPO plans in mid-December, meaning it could land on Wall Street ahead of CG and any other biotechs that might pencil in their plans before or during the rush of the JP Morgan Healthcare Conference next week. By the end of its first year on the public markets, CG could have topline data from a Phase III trial of its bladder cancer treatment candidate cretostimogene, per its S-1 filing. The biotech’s lead study, BOND-003, is testing the drug as a monotherapy in patients with BCG-unresponsive high-risk non-muscle invasive bladder cancer, or NMIBC. Formerly known as CG0070, the oncolytic virus is also being tested in combination with Merck’s Keytruda and in other NMIBC settings alone and in combination regimens. If the first Phase III trial is a success, CG plans to file for approval with a biologics license application. That could happen as soon as late 2024 or early 2025, CEO Arthur Kuan told Endpoints News at the time of the biotech’s $105 million crossover round in August 2023. Less than three months later, the biotech had confidentially filed its IPO plans with the SEC, according to documents revealed Tuesday. What started as Cold Genesys in 2010 is now one of multiple companies creating therapies for bladder cancer, including UroGen, which also plans a 2024 approval request; ImmunityBio, which just secured more money this week as it awaits an April PDUFA following a May 2023 rejection; and gene therapy biotech enGene, which began trading on the Nasdaq after a SPAC combination last November. CG is first attempting to treat patients who are unresponsive to Merck’s Bacillus Calmette-Guérin therapy, which has been in short supply for the past few years. “More than 20,000 patients may not have access to BCG, and that accumulates because that shortage is not going away,” Kuan said in the August interview. The company has ramped up spending over the past two years as it goes through late-stage development, but it still has a hefty balance sheet with $203.7 million in cash, equivalents and marketable securities at the end of September. In… #lucidquest #genetherapy #celltherapy

Evaluate your chemotherapy drugs with Replication Combing Assay Service in 2 weeks. We take care of each steps, from sample preparation to report analysis.   #RCA #Drugdiscovery #Chemotherapy #Oncology

💥 2024 has kicked off with a busy week of deals and collaborations in cell therapy, amounting to over $3bn: 🔹 AstraZeneca will acquire Gracell Biotechnologies for over $1bn to expand their next-gen cell therapy oncology and autoimmune pipeline and leverage their FasTCAR manufacturing platform (the first big pharma to back 𝘪𝘯 𝘷𝘪𝘷𝘰) 🔹 AbbVie and Umoja Biopharma enter strategic collaboration to develop novel in-situ CAR-Ts using their VivoVec™ gene delivery platform, with funding of up to $1.44bn 🔹 Umoja Biopharma also announced a development partnership with IASO BioTherapeutics（驯鹿生物）to develop both 𝘦𝘹 𝘷𝘪𝘷𝘰 and 𝘪𝘯 𝘷𝘪𝘷𝘰 CAR-Ts in oncology and autoimmunity 🔹 Boehringer Ingelheim and 3T Biosciences enter another strategic collaboration, with milestones up to £538.5m, to further progress their next-gen TCR-T programs 🔹 Boehringer Ingelheim have also licensed Enara Bio's Dark Antigen® platform to develop off-the-shelf cancer immunotherapies Unpack this news at the new 𝘐𝘯𝘷𝘦𝘴𝘵𝘰𝘳 & 𝘉𝘪𝘰𝘱𝘩𝘢𝘳𝘮𝘢 𝘗𝘢𝘳𝘵𝘯𝘦𝘳𝘴𝘩𝘪𝘱𝘴 𝘌𝘷𝘦𝘯𝘪𝘯𝘨 at the 7𝐭𝐡 𝐂𝐀𝐑-𝐓𝐂𝐑 𝐄𝐮𝐫𝐨𝐩𝐞 next month with David Fontana, Chris Moore, Caroline Haegeman, Stefano Quintini and Miguel Forte! Find out more: https://ter.li/dy8k8i

With the evolving massive parallel signature sequencing (MPSS) techniques, #geneticengineering, lab-on-a-chip methods, and personalized treatment, CAR-T cell therapies are escalating advancements in cancer care. Read our latest #blog to explore the recent advances and strategic collaborations among pharmaceutical enterprises to propel the launch of efficient treatments for solid tumors. Willing to innovate or proceed with the commercialization of cancer therapy, understand the market competition and regulatory protocols, or seek a reliable ally to pursue the technology development? Schedule a meeting with our technology expert Ravi Shankar by emailing us: contact@iebrain.com To know more, visit us: www.iebrain.com #cancertreatment #cartcelltherapy #solidtumors #healthcareinnovation #oncovision

Predictive Oncology Unveils Cutting-Edge 3D Cell Culture Models to Transform Cancer Drug Discovery 🔬 Predictive Oncology has introduced its innovative 3D cell culture model aimed at advancing cancer drug discovery and future drug development. These in vitro models are designed to mimic human tissue environments, preserving essential tumor interactions. They offer full customization for targeted tissues and compatibility with various cell types and drug categories, surpassing traditional 2D assays in accuracy. 💊 The 3D models provide a more representative method for in vivo clinical testing, potentially reducing the time to market, costs, and the need for animal testing. CEO Raymond F. Vennare emphasized the importance of incorporating complex 3D cell applications into global drug discovery processes to streamline development and cut down on clinical trial iterations. 🤖 The company's AI platform, PEDAL, boasts a 92% accuracy rate in predicting tumor responses to drugs, aiding in selecting optimal drug-tumor combinations. Predictive Oncology's comprehensive approach integrates AI and machine learning to expedite drug discovery, supported by its CLIA lab and GMP plants. 🌟 Senior VP Arlette Uihlein highlighted the promise of using 3D organoids and spheroids with their high-throughput platform to efficiently predict drug responses, marking a significant advancement in oncology modeling. This innovative approach aims to enhance cancer treatment development and provide more effective therapeutic solutions. For similar news, please follow our page: World Pharmaceutical Frontiers #CancerResearch #DrugDiscovery #3DCellCulture #BiotechnologyInnovation #worldpharmaceuticalfrontiers

⚔ AbbVie and Umoja Biopharma Forge Transformative Partnership in CAR-T Therapy Innovation In a groundbreaking collaboration, AbbVie and Umoja Biopharma have inked exclusive option and license agreements to pioneer in-situ generated CAR-T cell therapies for oncology. Leveraging Umoja Biopharma's proprietary VivoVecTM platform, this partnership aims to revolutionize cancer treatment paradigms, particularly in hematologic malignancies. AbbVie secures an exclusive option to license Umoja's CD19 directed in-situ generated CAR-T cell therapy candidates. This includes the lead clinical program, UB-VV111, currently advancing through the crucial IND-enabling phase, promising significant advancements in hematologic malignancies. A second agreement empowers AbbVie and Umoja Biopharma to collaboratively develop up to four additional in-situ generated CAR-T cell therapy candidates. The targets for discovery will be chosen by AbbVie, aligning with their commitment to expanding the horizons of conventional CAR-T approaches. 🔬 Umoja Biopharma's VivoVecTM platform is a pioneering gene delivery system, seamlessly integrating third-generation lentiviral vector gene delivery with a unique T-cell targeting and activation surface complex. This approach enables the in-vivo generation of CAR-T cells within the patient's body, mitigating challenges associated with traditional CAR-T therapies. 💼 AbbVie's upfront payments and equity investment in Umoja Biopharma underscore the strategic importance of this collaboration. Umoja stands to gain up to $1.44 billion in aggregate for option exercise fees, development and regulatory milestones, along with potential sales-based milestones and tiered royalties on global net sales. As AbbVie and Umoja Biopharma embark on this transformative journey, the collaboration represents a convergence of expertise, innovation, and a shared commitment to addressing unmet needs in cancer treatment. The exploration of in-situ CAR-T therapies holds immense promise, and both companies are poised to make significant strides in reshaping the landscape of oncology. #AbbVie #UmojaBiopharma #CARTTherapy #InnovationInOncology #BiopharmaCollaboration #MedicalAdvancements #HealthcareInnovation #PharmaFinances

OregonTherapeutics & Lantern Pharma Inc. (Nasdaq: LTRN) launch a strategic #artificialintelligence (#AI) collaboration to optimize #XCE853, a novel #cancerdrug candidate. Demonstrating efficacy in solid #tumor and hematological #cancers, XCE853 is poised for #IND-enabling development. Leveraging Lantern Pharma's AI platform, the partnership aims to enhance the efficacy of XCE853.  The collaboration's objectives include uncovering biomarkers and gene signatures associated with XCE853’s efficacy, identifying mechanisms of treatment resistance, and expanding its application to additional #cancer indications. Panna Sharma, CEO of Lantern Pharma, highlighted #RADR®'s ability to address data and modeling challenges, enabling informed decision-making in drug development. By Mithat Can Turan https://lnkd.in/depukyqn